Abstract
The protein kinase family presents remarkable opportunities for drug discovery and development targeting mainly to the ATP binding cleft. Cyclindependent kinases CDKs control the cell division in by controlling its sub phases. The regulation of CDKs is altered in a number of tumor types, and therefore CDKs are a particularly attractive target group of kinases with reference to proliferative disorders including cancer, but also extending to graft stenosis, and autoimmune disorders. Screening of chemical modulators of CDKs that modulate aberrant CDK activity might be beneficial for cancer therapy by directly inhibiting kinase activity, or influencing cell cycle “checkpoint” function, which is mediated through effects of exogenous cellular regulators of CDK activity. In this regard small molecule modulators such as flavopiridol and UCN-01 are in early clinical trials. Other more selective modulators of CDK function are being actively sought, and initial results with flavopiridol analogs, indirubins, paullones, and purine-based inhibitors will be considered.
Current Pharmaceutical Design
Title: Early Development of Cyclin Dependent Kinase Modulators
Volume: 7 Issue: 16
Author(s): K.K. Roy and E.A. Sausville
Affiliation:
Abstract: The protein kinase family presents remarkable opportunities for drug discovery and development targeting mainly to the ATP binding cleft. Cyclindependent kinases CDKs control the cell division in by controlling its sub phases. The regulation of CDKs is altered in a number of tumor types, and therefore CDKs are a particularly attractive target group of kinases with reference to proliferative disorders including cancer, but also extending to graft stenosis, and autoimmune disorders. Screening of chemical modulators of CDKs that modulate aberrant CDK activity might be beneficial for cancer therapy by directly inhibiting kinase activity, or influencing cell cycle “checkpoint” function, which is mediated through effects of exogenous cellular regulators of CDK activity. In this regard small molecule modulators such as flavopiridol and UCN-01 are in early clinical trials. Other more selective modulators of CDK function are being actively sought, and initial results with flavopiridol analogs, indirubins, paullones, and purine-based inhibitors will be considered.
Export Options
About this article
Cite this article as:
K.K. Roy and E.A. Sausville , Early Development of Cyclin Dependent Kinase Modulators, Current Pharmaceutical Design 2001; 7 (16) . https://dx.doi.org/10.2174/1381612013397230
DOI https://dx.doi.org/10.2174/1381612013397230 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design, Synthesis and PASS Assisted Evaluation of Novel 2-Substituted Benzimidazole Derivatives as Potent Anthelimintics
Medicinal Chemistry Monoamine Oxidase Inhibitory Action of Chalcones: A Mini Review
Central Nervous System Agents in Medicinal Chemistry YB-1 Protein and Multidrug Resistance of Tumor Cells
Current Signal Transduction Therapy The Expression Patterns and Clinical Significance of microRNAs in Liver Diseases and Hepatocellular Carcinoma
Current Pharmaceutical Design Synthesis of Some Coumarinyl Chalcones and their Antiproliferative Activity Against Breast Cancer Cell Lines
Letters in Drug Design & Discovery Chemotherapy Resistance Molecular Mechanism in Small Cell Lung Cancer
Current Molecular Medicine Generation of the Fluorescent HPV16 E7 Protein for Detection of Delivery In vitro
Protein & Peptide Letters Development and Characterization of Solid Dispersion System for Enhancing the Solubility and Dissolution Rate of Dietary Capsaicin
Current Drug Therapy Advances in Biologic Agents for the Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Clustering and Sampling of the c-Met Conformational Space: A Computational Drug Discovery Study
Combinatorial Chemistry & High Throughput Screening Recent Researches in Metal Supramolecular Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry A Genetic Algorithm- Back Propagation Artificial Neural Network Model to Quantify the Affinity of Flavonoids Toward P-Glycoprotein
Combinatorial Chemistry & High Throughput Screening Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells
Current Pharmaceutical Biotechnology Heat Shock Proteins: A Potential Anticancer Target
Current Drug Targets Editorial (Thematic Issue: Gene Transfer by Electric Fields)
Current Gene Therapy Notch Signaling in Mammalian Intestinal Stem Cells: Determining Cell Fate and Maintaining Homeostasis
Current Stem Cell Research & Therapy CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Editorial (Thematic Issue: Emerging Azoles: Structure Function Relationship and Their Therapeutic Potential)
The Natural Products Journal Syntheses, Molecular Targets and Antitumor Activities of Novel Triptycene Bisquinones and 1,4-Anthracenedione Analogs
Anti-Cancer Agents in Medicinal Chemistry Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment
Recent Patents on Anti-Cancer Drug Discovery